Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.90M | -27.40M | -330.50M | -100.00K | -42.50M |
| Total Depreciation and Amortization | 12.60M | 12.60M | 14.10M | 14.40M | 14.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.50M | 14.50M | 329.80M | -18.50M | 58.50M |
| Change in Net Operating Assets | -1.60M | 21.40M | -27.00M | -12.10M | -24.20M |
| Cash from Operations | 10.60M | 21.10M | -13.60M | -16.30M | 6.60M |
| Capital Expenditure | -4.70M | -2.80M | -2.80M | -5.30M | -3.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | -1.30M | -3.40M | -4.10M | -3.00M | -2.30M |
| Cash from Investing | -6.00M | -6.20M | -6.90M | -8.30M | -5.90M |
| Total Debt Issued | 0.00 | 125.00M | 0.00 | 40.00M | 20.00M |
| Total Debt Repaid | 300.00K | -60.10M | -100.00K | -20.60M | -19.20M |
| Issuance of Common Stock | 600.00K | 0.00 | 2.70M | -- | 2.90M |
| Repurchase of Common Stock | -1.20M | -300.00K | 0.00 | -5.80M | -1.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.90M | -8.40M | -- | -- | -400.00K |
| Cash from Financing | -8.20M | 56.20M | 2.60M | 13.60M | 2.10M |
| Foreign Exchange rate Adjustments | 100.00K | 0.00 | 600.00K | 100.00K | -700.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.50M | 71.10M | -17.30M | -10.90M | 2.10M |